Nuevocor
nuevocor.com
Biotechnology
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$45M
1 round on record
Latest round
$45M
Series B · May 2025 · 17 mo ago
Team
51-200
employees, estimated range
Backers
2
Angelini Ventures, Kurma Partners
The money's age
Due for its next round
17 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 28
New executive Nuevocor Appoints Dr. Monica Shah as Chief Medical Officer · PRNewswire
Jan 7
New executive Nuevocor Appoints Al Gianchetti as Chief Executive Officer · businesswire.com
May 6, 2025
Raised a round Series B $45M · led by Kurma Partners · The Manila Times
Jan 24, 2025
Board appointment Nuevocor Welcomes Andreas Wallnöfer as Chairman of the Board of Directors · PRNewswire
2017
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | May 2025 | $45M | Kurma Partners lead, Angelini Ventures lead, EDBI, ClavystBio, Boehringer Ingelheim Venture Fund | The Manila Times |
Backed byfrom the funds' portfolios and accelerator catalogs
Angelini Ventures 
Kurma Partners News
Nuevocor Appoints Dr. Monica Shah as Chief Medical Officer
/PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company developing novel therapies for patients suffering from life-threatening cardiomyopathies,...
Read more
Report
Nuevocor Strengthens Board with Appointment of Thierry Abribat
SINGAPORE, July 7, 2025 /PRNewswire/ -- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the appointment of Dr. Thierry Abribat to its Board of Directors.
Read more
Report
Nuevocor: $45 Million Series B Raised For Clinical Development Of Novel Mechanobiology-Centered Therapy For Cardiomyopathy
Nuevocor, a Singapore-headquartered IND-stage biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, announced the completion of a $45 million Series B financing. Kurma Partners and Angelini Ventures co-led the fund
Read more
Report
Nuevocor Closes US$45 Million Series B Financing for Clinical Development of Novel Mechanobiology-Centered Therapy for Cardiomyopathy
- Round co-led by new investors, Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund
Read more
Report
Nuevocor Welcomes Andreas Wallnöfer as Chairman of the Board of Directors
/PRNewswire/ -- Nuevocor, an IND-stage biotechnology company dedicated to developing functional cures to treat cardiomyopathies with aberrant mechanobiology,...
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Financials
Total raised
$45M
Latest round
Series B
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series B | 2025 | $45M | Details |